How were Albireo Pharma's earnings last quarter?

Albireo Pharma, Inc. (NASDAQ:ALBO) issued its quarterly earnings results on Thursday, November, 4th. The biopharmaceutical company reported $2.90 EPS for the quarter, beating analysts' consensus estimates of ($0.38) by $3.28. The biopharmaceutical company had revenue of $3.66 million for the quarter, compared to analyst estimates of $22.33 million. Albireo Pharma had a negative trailing twelve-month return on equity of 97.13% and a negative net margin of 228.51%. During the same period last year, the company earned ($1.96) earnings per share.

What other stocks do shareholders of Albireo Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Albireo Pharma investors own include Energy Transfer (ET) , Heat Biologics (HTBX) , Amarin (AMRN) , Exelixis (EXEL) , Palatin Technologies (PTN) , GW Pharmaceuticals (GWPH) , Viking Therapeutics (VKTX) , Agenus (AGEN) , OPKO Health (OPK) and Pfizer (PFE) .

NASDAQ:ALBO

Albireo Pharma (ALBO) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free ALBO Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $43.99
▼
$44.90
50-Day Range: $43.50
▼
$44.95
52-Week Range: $16.02
▼
$45.23

Volume: 1.24 million shs
Average Volume: 704,539 shs
Market Capitalization: $913.91 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Albireo Pharma alerts:

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Albireo Pharma Stock (NASDAQ:ALBO)

Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA.

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

ALBO Stock News Headlines

January 19, 2024 | bizjournals.com

Prospect Park II in Fort Lauderdale

October 1, 2023 | investing.com

ALBO Historical Data

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 4, 2023 | finanznachrichten.de

Ipsen Pharma: Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolio

February 25, 2023 | seekingalpha.com

ALBO Albireo Pharma, Inc.

February 18, 2023 | uk.finance.yahoo.com

Albireo Pharma, Inc. (ALBO)

February 14, 2023 | marketwatch.com

Albireo Gets FDA Priority Review of Bylvay in Alagille Syndrome >ALBO

February 14, 2023 | finance.yahoo.com

FDA Grants June 15, 2023 PDUFA Date to Albireo for Bylvay® in Alagille Syndrome

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

January 24, 2023 | reuters.com

ALBO.PH - | Stock Price & Latest News | Reuters

January 21, 2023 | finance.yahoo.com

Why These Two Biotech Stocks Blasted Higher This Week

January 11, 2023 | msn.com

Cowen & Co. Downgrades Albireo Pharma: Here's What You Need To Know

January 11, 2023 | msn.com

Analysts move to downgrade Albireo Pharma after Ipsen's proposed acquisition

January 11, 2023 | nasdaq.com

Albireo Pharma Spikes On Agreement To Be Acquired By Ipsen

January 11, 2023 | markets.businessinsider.com

Expert Ratings for Albireo Pharma

January 9, 2023 | benzinga.com

Shareholder Alert: Ademi LLP investigates whether Albireo Pharma, Inc. has obtained a Fair Price in its transaction with Ipsen

January 9, 2023 | technews.tmcnet.com

ALBO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Albireo Pharma, Inc. Is Fair to Shareholders

January 9, 2023 | finance.yahoo.com

France-Based Ipsen Acquires Albireo Pharma Enriching Its Rare Disease Portfolio, Pipeline

January 2, 2023 | seekingalpha.com

Albireo: Slowly Capturing Some Of The Liver Disease Market

December 21, 2022 | finance.yahoo.com

We're Not Very Worried About Albireo Pharma's (NASDAQ:ALBO) Cash Burn Rate

December 6, 2022 | finance.yahoo.com

Albireo Appoints Paul Streck, M.D., as Chief Medical Officer & Craig Hopkinson, M.D., to Board of Directors

November 30, 2022 | finance.yahoo.com

Reimbursed Access to Bylvay® (odevixibat) Approved in France for Patients with PFIC 1 & 2

November 10, 2022 | finance.yahoo.com

Albireo Pharma (NASDAQ:ALBO) dips 16% this week as increasing losses might not be inspiring confidence among its investors

November 9, 2022 | finance.yahoo.com

Albireo to Participate in Jefferies London Healthcare Conference

November 9, 2022 | seekingalpha.com

Albireo Pharma, Inc. (ALBO) Q3 2022 Earnings Call Transcript

November 8, 2022 | finance.yahoo.com

Albireo Pharma (ALBO) Reports Q3 Loss, Tops Revenue Estimates

November 8, 2022 | finance.yahoo.com

Albireo Reports Q3 2022 Financial Results and Business Update

See More Headlines

Receive ALBO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Albireo Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/04/2021
Today: 4/17/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ALBO
CUSIP: N/A
CIK: 1322505
Web: www.albireopharma.com
Phone: (857) 254-5555
Fax: 203-796-5001
Employees: 130
Year Founded: 2003

Profitability

EPS (Most Recent Fiscal Year): ($6.72)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-34,030,000.00
Net Margins: -228.51%
Pretax Margin: -235.11%
Return on Equity: -97.13%
Return on Assets: -46.89%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.32
Quick Ratio: 6.23

Sales & Book Value

Annual Sales: $40.58 million
Price / Sales: 22.52
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $9.11 per share
Price / Book: 4.85

Miscellaneous

Outstanding Shares: 20,700,000
Free Float: 19,273,000
Market Cap: $913.91 million
Optionable: Optionable
Beta: 1.03

Social Links

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Ronald H. W. Cooper
President, Chief Executive Officer & Director
Simon John Harford
Chief Financial Officer & Treasurer
Jan Peter Mattsson
Chief Scientific Officer, Managing Director-Sweden
Joan Connolly
Chief Technology Officer
Paul D. Streck
Chief Medical Officer

Key Competitors

View All Competitors

ALBO Stock Analysis - Frequently Asked Questions

How were Albireo Pharma's earnings last quarter?: Albireo Pharma, Inc. (NASDAQ:ALBO) issued its quarterly earnings results on Thursday, November, 4th. The biopharmaceutical company reported $2.90 EPS for the quarter, beating analysts' consensus estimates of ($0.38) by $3.28. The biopharmaceutical company had revenue of $3.66 million for the quarter, compared to analyst estimates of $22.33 million. Albireo Pharma had a negative trailing twelve-month return on equity of 97.13% and a negative net margin of 228.51%. During the same period last year, the company earned ($1.96) earnings per share.
What other stocks do shareholders of Albireo Pharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Albireo Pharma investors own include Energy Transfer (ET), Heat Biologics (HTBX), Amarin (AMRN), Exelixis (EXEL), Palatin Technologies (PTN), GW Pharmaceuticals (GWPH), Viking Therapeutics (VKTX), Agenus (AGEN), OPKO Health (OPK) and Pfizer (PFE).

This page (NASDAQ:ALBO) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Albireo Pharma (ALBO) Stock Price, News & Analysis

About Albireo Pharma Stock (NASDAQ:ALBO)

ALBO Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

ALBO Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info